Molgramostim Open-label

Phase 3

Molgramostim Open-label is one of 3 therapeutic programs targeting Autoimmune Pulmonary Alveolar Proteinosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Autoimmune Pulmonary Alveolar ProteinosisActive, not recruiting

Autoimmune Pulmonary Alveolar ProteinosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Autoimmune Pulmonary Alveolar Proteinosis

#DrugCompanyPhaseTrials

GM-CSF

YY-mAbs Therapeutics

Phase 2

3 2

Molgramostim

SSavara Inc.

Phase 3

5 3

Molgramostim Open-label

SSavara Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Autoimmune Pulmonary Alveolar Proteinosis

NCT04544293

Clinical

Trials by Indication[1]

Autoimmune Pulmonary Alveolar Proteinosis1 trial

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting·SSavara Inc.·Phase 3·NCT04544293·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Molgramostim Open-label. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Molgramostim Open-label. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Savara Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSavara Inc.

Molgramostim Open-label

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Autoimmune Pulmonary Alveolar Proteinosis1 trial

References

Drug Info

Quick Facts

Related News